← Back to headlines
Gilead to Acquire Ouro Medicines in $2.18 Billion Deal to Expand Inflammation Pipeline
Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.
27 Mar, 00:55 — 27 Mar, 00:55
Sources
Showing 1 of 1 sources
